STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
ZIOP ZIOPHARM ONCOLOGY INCORPORATED StockScouter® Report
2
StockScouter® Score
ZIOPHARM ONCOLOGY INCORPORATED, a micro cap company in the healthcare sector, is expected to underperform the market over the next six months with slightly higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- The multi-period measure of relative price change and consistency is well below average. Negative
- Moving average analysis for ZIOP suggests weak price movement over the medium term. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
C
D
F
F